| Code | CSB-RA006163MB16HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Tuvonralimab, targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA4), a critical immune checkpoint receptor expressed on T cells. CTLA4 functions as a negative regulator of T cell activation by competing with the costimulatory receptor CD28 for binding to B7 ligands (CD80/CD86) on antigen-presenting cells. By delivering inhibitory signals, CTLA4 maintains immune homeostasis and prevents excessive T cell responses. Dysregulation of CTLA4-mediated immune suppression is implicated in various cancers, where tumors exploit this pathway to evade immune surveillance, as well as in autoimmune disorders where CTLA4 deficiency can lead to uncontrolled immune activation.
Tuvonralimab represents a next-generation anti-CTLA4 antibody engineered to block CTLA4 inhibitory function while potentially minimizing toxicity associated with conventional CTLA4 blockade. This biosimilar antibody serves as a valuable research tool for investigating CTLA4 biology, immune checkpoint mechanisms, tumor immunology, and T cell regulation in various experimental models. It supports studies exploring combination immunotherapy strategies and mechanisms of immune-related adverse events.
There are currently no reviews for this product.